Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress
– Updated dataset to be presented in oral presentation at EHA2025 Congress –
SAN DIEGO and TOKYO, May 14, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, 'Kura') and Kyowa Kirin Co., Ltd. (TSE: 4151, 'Kyowa Kirin') today announced that an abstract highlighting clinical data from the KOMET-007 combination trial of ziftomenib, a once-daily, oral investigational menin inhibitor, has been accepted for presentation at the upcoming 2025 European Hematology Association (EHA) Congress, to be held in Milan, Italy, from June 12-15, 2025.
KOMET-007 is a multicenter Phase 1 trial of ziftomenib in combination with standards of care, including cytarabine plus daunorubicin (7+3) and venetoclax/azacitidine (ven/aza), in patients with NPM1-mutant (NPM1-m) and KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML). The data presented at EHA will be from the Phase 1a dose-escalation and Phase 1b dose-expansion portions of the trial, in the cohort evaluating ziftomenib in combination with 7+3 in newly diagnosed patients with AML.
'The latest findings from the KOMET-007 trial underscore the potential of the combination of ziftomenib with intensive chemotherapy for newly diagnosed patients, strengthening our confidence in its role as a potential treatment option for a broad segment of the AML community,' said Mollie Leoni, M.D., Chief Medical Officer of Kura Oncology. 'The Phase 1a/b KOMET-007 trial positions us to further evaluate this combination, and its potential to expand treatment options for AML patients, in the upcoming pivotal Phase 3 KOMET-017 trial.'
In addition to the oral presentation, two abstracts for the KOMET-001 and KOMET-017 trials have been accepted for an encore presentation and publication, respectively. Session titles and information for all three abstracts are listed below and are now available on the EHAweb.org website. Updated data from the published abstract for KOMET-007 will be disclosed during the oral presentation.
Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed -m or -r Acute Myeloid Leukemia (AML): Updated Phase 1a/b Results from KOMET-007Session: s411. Menin inhibitors and venetoclax-based regimens in AML treatmentDate and Session Time: Thursday, June 12, 2025; 5:00PM - 6:15PM CESTLocation: Allianz MiCo, Milano Convention Centre, AuditoriumPublication Number: S136
Ziftomenib in Relapsed/Refractory -Mutant Acute Myeloid Leukemia: Phase 1b/2 Clinical Activity and Safety Results from the Pivotal KOMET-001 Study Session: Poster Session 1Date and Time: Friday, June 13, 2025; 6:30 PM - 7:30 PM CESTLocation: Allianz MiCo, Milano Convention Centre, Poster HallPublication Number: PF473
Registrational Phase 3 Study of Ziftomenib in Combination with Non-Intensive or Intensive Chemotherapy for Newly Diagnosed -m and/or -r Acute Myeloid Leukemia (AML): The KOMET-017 Trial Online Publication OnlyPublication Number: PB2573
Copies of the presentations will be available on Kura's website at www.kuraoncology.com/pipeline/publications/ following presentation at the meeting.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory (R/R) NPM1-m AML. In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in KOMET-001, a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-m AML, has been completed, and in the second quarter of 2025, the companies announced submission of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-m AML. Kura and Kyowa Kirin are conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-m and KMT2A-r AML. KO-2806, a next-generation farnesyl transferase inhibitor (FTI), is being evaluated in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. For additional information, please visit Kura's website at https://kuraoncology.com/ and follow us on X and LinkedIn.
About Kyowa Kirin
Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, Kyowa Kirin has invested in drug discovery and biotechnology innovation for more than 70 years and is currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato-oncology and rare diseases. A shared commitment to Kyowa Kirin's values, to sustainable growth, and to making people smile unites Kyowa Kirin across the globe. You can learn more about the business of Kyowa Kirin at www.kyowakirin.com.
Kura Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of ziftomenib; potential benefits of combining ziftomenib with intensive chemotherapy and the expected timing and presentation of results and data from clinical trials. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, the risk that the collaboration with Kyowa Kirin is unsuccessful, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words 'may,' 'will,' 'would,' 'could,' 'should,' 'believes,' 'estimates,' 'projects,' 'promise,' 'potential,' 'expects,' 'plans,' 'anticipates,' 'intends,' 'continues,' 'designed,' 'goal,' or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Kura Contacts
Investors: Patti Bank Managing Director(415) 513-1284patti.bank@icrhealthcare.com
Media:media@kuraoncology.com
Kyowa Kirin Contacts
Investors: Ryohei Kawaiir@kyowakirin.com
Media, Global:Wataru Suzuki, media@kyowakirin.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
27 minutes ago
- Fast Company
AstraZeneca announces $50 billion investment in U.S. as Trump's tariffs loom
AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy. The investment will fund a new drug manufacturing facility in Virginia and expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, it said in a statement. It will also upgrade the Anglo-Swedish drugmaker's U.S. clinical trial supply network and support ongoing investment in novel medicines. On Monday, AstraZeneca said the expansion supports its ambition to reach $80 billion in annual revenue by 2030, with half coming from the U.S. The U.S. accounted for more than 40% of AstraZeneca's annual revenue in 2024, and the company had been prioritising the market — the world's largest, worth $635 billion — before Trump's return to office. The move to scale up its U.S. footprint is the latest by a drugmaker as Trump threatens to impose import tariffs on the industry and seeks to boost domestic manufacturing. The sector has historically been spared from trade disputes. Trump has called on pharma companies to make more of the medicines they sell in the U.S. within the country, rather than importing active ingredients or finished medicines. He is also pushing for prices in the U.S. to fall to what other countries pay. CEO Pascal Soriot announced the plans in Washington, saying he believes that drug prices need to rise elsewhere and 'equalize' with other countries effectively contributing more to research and development costs. 'The United States cannot build or carry the cost of R&D for the entire world,' he said. U.S. Commerce Secretary Howard Lutnick's department is leading a probe into pharmaceutical imports that could pave the way for new tariffs. 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness,' said Lutnick in a statement issued by AstraZeneca. While Trump has repeatedly threatened tariffs on the sector, he signalled earlier this month that companies would be given a year to 18 months to 'get their act together' before any levies take effect. The company said that the timing and location of the announcement was linked to the U.S. policy environment, though some of the spending would have occurred regardless so that the infrastructure for future medicines was in place. The pledge is in addition to the $3.5 billion in investments the company announced in November 2024, the statement said. PLEDGES The $50 billion pledge matches the commitment announced by Swiss rival Roche in April and follows new spending plans unveiled this year by Eli Lilly & Co, Johnson & Johnson, Novartis, and Sanofi. Also present at the announcement was Virginia State Governor Glenn Youngkin, a vocal Trump ally who has defended the administration's tariff policies. The new Virginia facility — the company's largest single manufacturing investment — will produce active ingredients for AstraZeneca's experimental weight-loss medicines, including its oral GLP-1 candidate and an oral PCSK9 inhibitor for cholesterol management, it said. The company said the investment could create tens of thousands of new jobs, but declined to give specifics. It employs about 18,000 people in the U.S. and has a global workforce of about 90,000. In January it scrapped plans to invest 450 million pounds ($607.1 million) in its vaccine manufacturing plant in northern England, citing a cut in government support. Earlier this month, The Times reported the company was considering moving its stock market listing from London, where it is the exchange's most valuable company worth 159 billion pounds, to the U.S. The company declined to comment.
Hamilton Spectator
an hour ago
- Hamilton Spectator
Why Ready-to-Eat, Home-Cooked Meals Are the Next Big Thing in Food Delivery: A TiffinStash Perspective
A wholesome Indian thali with nutrients rich sabzis, dals, millets, and handmade rotis — just like the ready-to-eat, homely meals TiffinStash delivers. TORONTO, July 22, 2025 (GLOBE NEWSWIRE) — As food delivery matures into a $75.8 B market in North America—with a CAGR of about 12% through 2033 —consumer priorities are shifting from convenience to authentic, healthy, and comfort of home meals. Toronto's leading tiffin marketplace, TiffinStash believes this signals a pivotal shift: home kitchens, not dark or ghost ones, are poised to define the next wave of food tech. ' TiffinStash isn't just solving a food problem—we're bridging emotional gaps ,' says Krish Shah, Founder & CEO of TiffinStash. ' People miss the comfort of familiar meals made with care. They want something that feels like home, from someone who understands their pace of life and what real food means to them.' A Market Hungry for Homemade North America's online food delivery market reached $38 billion in 2024, projected to grow to $110 billion by 2034, with ethnic and home-style meals emerging as the fastest-growing subcategories according to Future Market Insights. Despite this boom, most consumers still value the comfort of home-cooked meals—something missing from most restaurant-style delivery menus. TiffinStash understands this growing shift in how people want to eat. In response, it became the first platform in Canada to help home-based chefs get licensed and to publicly list verified, hygiene-compliant home kitchens—ensuring safety, dignity, and trust not just for convenience, but communities. Beyond Meal Kits: Authenticity & Culture In the aftermath of COVID, cook-and-eat meal kits surged in popularity as more people stayed home and embraced cooking—making up 61% of the market in 2023 (approx. $12 billion) according to Wikipedia. But as life returns to its usual pace, consumer preferences are rapidly shifting. The ready-to-eat meals segment is now the fastest-growing in North America, projected to reach US $16.39 billion by 2025, growing at an 11.66% CAGR through 2029, according to Statista. TiffinStash caters to this demand by delivering freshly prepared, home-style heat-and-eat meals daily—combining authenticity with everyday convenience. Healthier Choices, Rooted in Tradition As consumers grow more conscious about what they eat, the demand for meals that are both nourishing and culturally familiar is rising. Research from the Harvard School of Public Health shows that home-cooked meals are typically lower in sodium, added sugar, and processed ingredients compared to restaurant or takeout options, contributing to better overall health outcomes. TiffinStash brings that balance to the table—offering a curated range of healthy, protein-rich tiffin meals—both vegetarian and non-vegetarian. From quinoa and tofu to grilled chicken and seasonal sabzis, these healthy meals balance taste and nutrition without the need for calorie counting or compromise. TiffinStash: Reinventing Food Delivery with Home Kitchens Since launch, TiffinStash has redefined tiffin delivery by enabling 60+ licensed seller listings to serve thousands of South Asian meals across the Greater Toronto Area, with 75% of repeat customers. Built without venture capital, the platform runs on a tech-enabled, trust-first model that balances affordability and cultural authenticity. ' We didn't raise venture capital, but we raised something more powerful—trust ,' adds Krish Shah. TiffinStash isn't just delivering tiffin—it's building a movement powered by comfort food, community empowerment, and cultural pride. About TiffinStash Launched in 2021, TiffinStash is a Toronto-based marketplace connecting customers with diverse multi cuisine tiffin sellers. The platform offers flexible, daily deliveries of freshly prepared tiffins across the GTA, with customizable subscription plans and free delivery. TiffinStash also provides catering services for events and large gatherings. By enabling sellers to list their services, TiffinStash offers a modern solution to a cherished tradition, delivering quality home-style meals to customers across the region. For more information, visit or follow TiffinStash on Instagram . Media Inquiries TiffinStash Inc. media@ +1 437-937-3267 A photo accompanying this announcement is available at
Hamilton Spectator
an hour ago
- Hamilton Spectator
Ambiq Launches Two New Edge AI Runtime Solutions
AUSTIN, Texas, July 22, 2025 (GLOBE NEWSWIRE) — Ambiq Micro, Inc. ('Ambiq'), a technology leader in ultra-low-power semiconductor solutions for edge AI, today unveils HeliosRT (Runtime) and HeliosAOT (Ahead-of-Time), two new edge AI runtime solutions optimized for the Ambiq Apollo Systems-on-Chip (SoCs) family. These developer tools are designed to significantly enhance the performance and energy efficiency of AI models for the unique demands of edge computing environments. Addressing Critical Edge AI Challenges As AI workloads increasingly migrate to edge devices, developers face growing pressure to deliver high performance within strict power budgets. Traditional AI frameworks often struggle in ultra-low-power scenarios, making it difficult to deploy sophisticated AI models in battery-powered devices, such as wearables, hearables, IoT sensors, and industrial monitors. Ambiq's new runtime solutions expand its growing portfolio of developer-centric tools, designed to help engineers unlock the full potential of Apollo SoCs. HeliosRT and HeliosAOT offer flexible, high-performance deployment options for edge AI across a wide range of applications, from digital health and smart homes to industrial automation and beyond. HeliosRT: Power-Optimized LiteRT HeliosRT is a performance-enhanced implementation of LiteRT (formerly TensorFlow Lite for Microcontrollers) that is tailored for energy-constrained environments. Fully compatible with existing TensorFlow workflows, HeliosRT introduces key improvements: HeliosAOT: Compiling LiteRT to Optimized C Code HeliosAOT introduces a ground-up, ahead-of-time compiler that transforms TensorFlow Lite models directly into embedded C code for edge AI deployment. This innovative approach offers runtime-level, or better, performance with additional benefits: 'The intersection of developer experience and power efficiency is our north star,' said Carlos Morales, VP of AI at Ambiq. 'HeliosRT and HeliosAOT are designed to integrate seamlessly with existing AI development pipelines while delivering the performance and efficiency gains that edge applications demand. We believe this is a major step forward in making sophisticated AI truly ubiquitous.' Powered by SPOT® and Real-World Success Both Helios solutions are built on Ambiq's patented Sub-threshold Power Optimized Technology (SPOT), which is the foundation behind over 270 million devices deployed worldwide. Leveraging years of hardware-software co-design, these tools deliver measurable performance gains and streamlined deployment for developers targeting the edge. Availability Both solutions are supported with robust documentation, ready-to-use examples, and dedicated engineering assistance for Ambiq customers. About Ambiq Ambiq's mission is to enable intelligence (artificial intelligence (AI) and beyond) everywhere by delivering the lowest power semiconductor solutions. Ambiq enables its customers to deliver AI compute at the edge where power consumption challenges are the most profound. Ambiq's technology innovations, built on the patented and proprietary sub-threshold power optimized technology (SPOT), fundamentally deliver a multi-fold improvement in power consumption over traditional semiconductor designs. Ambiq has powered over 270 million devices to date. For more information, visit . Contact Charlene Wan VP of Corporate Marketing and Investor Relations cwan@ +1.512.879.2850 A photo accompanying this announcement is available at
